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Streptococcus pneumoniae, also known as the pneumococcus, is an important cause of morbidity
and mortality in the developed and developing world. Pneumococcal conjugate vaccines were first
introduced for routine use in the USA in 2000, although the seven-valent pneumococcal
conjugate vaccine (PCV7) was not introduced into the UK’s routine childhood immunization
programme until September 2006. After its introduction, a marked decrease in the incidence of
pneumococcal disease was observed, both in the vaccinated and unvaccinated UK populations.
However, pneumococci are highly diverse and serotype prevalence is dynamic. Conversely, PCV7
targets only a limited number of capsular types, which appears to confer a limited lifespan to the
observed beneficial effects. Shifts in serotype distribution have been detected for both non-
invasive and invasive disease reported since PCV7 introduction, both in the UK and elsewhere.
The pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix;
GlaxoSmithKline) and 13-valent pneumococcal conjugate vaccine (PCV13, Prevenar 13; Pfizer)
have been newly licensed. The potential coverage of the 10- and 13-valent conjugate vaccines
has also altered alongside serotype shifts. Nonetheless, the mechanism of how PCV7 has
influenced serotype shift is not clear-cut as the epidemiology of serotype prevalence is complex.
Other factors also influence prevalence and incidence of pneumococcal carriage and disease,
such as pneumococcal diversity, levels of antibiotic use and the presence of risk groups.
Continued surveillance and identification of factors influencing serotype distribution are essential
to allow rational vaccine design, implementation and continued effective control of pneumococcal
disease.
Introduction
Streptococcus pneumoniae is a Gram-positive encapsulated
bacterium. Currently 46 serogroups and 93 serotypes have
been documented, the latest additions being serotype 6C
(Park et al., 2007b), serotype 6D (Jin et al., 2009) and
serotype 11E (Calix & Nahm, 2010). Capsular polysacchar-
ides are highly immunogenic and are the main target for
pneumococcal vaccines. However, the bacterium is capable
of transformation, the horizontal exchange of genetic
information, at both the intra- and interspecies level. This
recombination of genetic material can result in subtle
changes, which impact on the disease biology of strains and
can also allow capsular switch to occur (Silva et al., 2006).
This phenomenon results from recombination of heter-
ologous DNA at the capsular locus. As a consequence, clonal
isolates, as determined by multilocus sequence typing, can
express different polysaccharide capsules (serotype). Isolates
of the same serotype can also be of different sequence type
(ST) (Coffey et al., 1998). The polysaccharide capsule is a
key component of virulence, and serotypes differ in their
association with invasive disease, antibiotic resistance and
outbreak potential (Brueggemann et al., 2003; Magee &
Yother, 2001; Weinberger et al., 2009).
The pneumococcal niche
Humans are the major reservoir of S. pneumoniae, carrying
the bacteria asymptomatically in the nasopharynx (Hussain
et al., 2005). Within the human population, young children
are the key source of pneumococci. Prior to the seven-
valent polysaccharide conjugate vaccine (PCV7) introduc-
tion in the UK, a carriage rate of 45% had been reported in
children under 2 years old, compared to only 8% in those
older than 18 (Hussain et al., 2005).
Despite being part of the respiratory commensal flora, the
pneumococcus is also responsible for significant morbidity
Journal of Medical Microbiology (2011), 60, 1–8 DOI 10.1099/jmm.0.020016-0
020016 G 2011 SGM Printed in Great Britain 1
and mortality in the UK and worldwide (Melegaro et al.,
2006; Mulholland, 2007). Pneumococcal disease ranges
from acute otitis media (AOM) through to pneumonia and
invasive disease (IPD) such as meningitis and septicaemia.
Certain populations are at high risk of IPD and other
pneumococcal diseases. These include infants under 2
years old, for whom a UK pre-PCV7 study estimated 15
pneumococcal meningitis cases per 100 000 (Melegaro
et al., 2006). The elderly are also at risk, with approximately
45 cases of IPD per 100 000 occurring pre-PCV7 in persons
over 65 years in Scotland (Kyaw et al., 2003). Additional
risk groups for serious pneumococcal infection include
children between 2 and 5 years old and the immunocom-
promised (Burman et al., 1985; Kyaw et al., 2003).
Control of pneumococcal disease
The 23-valent polysaccharide vaccine (PPV, Pneumovax;
Merck) has been available for over 25 years. This vaccine is
used today to vaccinate at-risk adults and the elderly.
Unfortunately, immunization with PPV has recently been
found to be largely unsuccessful in the UK elderly population
(Joint Committee on Vaccination and Immunisation, 2009).
In addition, PPV is known to elicit a T-cell-independent
immune response, which is underdeveloped in those under 2
years old (Stein, 1992). Conjugate vaccines were designed to
improve efficacy in those under 2 years old.
PCV7 Prevenar (Pfizer, previously Wyeth) was first
recommended for use in the US in the year 2000
(Committee on Infectious Diseases, 2000). The vaccine
contains the capsular polysaccharide of seven serotypes,
conjugated to CRM197, a non-toxic diphtheria variant
carrier protein (Eskola et al., 2001). This immunogenic
protein increases the vaccine efficacy in the young by
inducing a T-cell-dependent response (Black et al., 2000;
Rennels et al., 1998). The seven serotypes included in the
vaccine – 4, 6B, 9V, 14, 18C, 19F and 23F – were selected as
they caused the majority of invasive disease in the US
(Hausdorff et al., 2000). These serotypes are also associated
with high antibiotic resistance (Hicks et al., 2007; Tyrrell
et al., 2009).
PCV7 impact in the UK
PCV7 vaccination in the UK was predicted to result in a
decrease in pneumococcal disease incidence (Clarke et al.,
2006), as described in the US (CDC, 2005), where PCV7
also resulted in a reduction in pneumococcal antibiotic
non-susceptibility (Richter et al., 2009). In September
2006, PCV7 was added to the UK routine childhood
immunization programme to help reduce the burden of
pneumococcal disease (Department of Health, 2006).
Serotype surveillance data for IPD in England, Wales and
Scotland since PCV7 vaccine introduction are being
continuously collected (www.hpa.org.uk, www.hps.scot.
nhs.uk). Current data for England and Wales (Kaye
et al., 2009) show a 41% decrease in the number of IPD
cases in those aged 5 years and under between 2005–2006
(797 cases) and 2007–2008 (470 cases). This is primarily a
result of a dramatic decrease in the number of IPD cases
caused by vaccine types (VTs) in children ¡5 years old.
This decrease can also be clearly seen when comparing the
cumulative total of cases reported in the under 5s by week
20 of 2006, 2007 and 2010 (Table 1). VT disease, previously
accounting for 70% of cases in this age group during
2005–2006, reduced to only 24% in 2007–2008. These
overall trends have also been observed in Scotland (Shakir
et al., 2009).
In addition to the decrease in IPD in the vaccinated
population, herd immunity to VT pneumococci has been
induced in the UK population as an indirect effect of infant
PCV7 immunization. A decrease in VT IPD incidence has
been seen in children over the age of 5 and adults, who are
largely unvaccinated (Kaye et al., 2009). The level of herd
immunity has been suggested to increase with the number
of doses given (Haber et al., 2007). Prior to this
observation, surveillance carried out in the US demon-
strated a 42% fall in the incidence of IPD in infants
,90 days old (Carter, 2006), indicating that herd immu-
nity can also extend to those not yet old enough to be
vaccinated or to have completed the vaccination course. A
US model also predicted that even incomplete coverage
and/or limited dose schedules would still confer herd
immunity (Haber et al., 2007). Herd immunity, primarily
due to reduced exposure through decreased carriage and
transmission from the vaccinated population, contributes
extensively to the overall impact and cost-effectiveness of
vaccination (CDC, 2005; Melegaro & Edmunds, 2004).
Without such effects, the PCV7 introduction may not have
been considered economically viable in the UK (Melegaro
& Edmunds, 2004).
Serotype replacement
Following PCV7 introduction in the US, a shift in the
prevalent serotypes circulating in the population and
causing disease was observed, termed ‘serotype replace-
ment’ (McEllistrem et al., 2003). This was predicted to be
mirrored in the UK (Spratt & Greenwood, 2000).
Table 1. Approximate number of IPD reports in those,5 years
old by week 20 of 2006, 2007 or 2010
Data adapted from Current Epidemiology of Invasive Pneumococcal
Disease (IPD) graphs, HPA website (www.hpa.org.uk).
Year In PCV7 Not in PCV7 Total cases
2006 400 150 550
2007 275 175 450
2010 25 375 400
Increaseq/decreaseQ Q q Q
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Although there has been a dramatic reduction in VT IPD,
the phenomenon of ‘replacement disease’ has occurred in
the UK. Replacement disease is due to the increase in non-
vaccine serotype (NVT) IPD cases, which has greatly offset
the decrease in VT IPD (Table 1). The total number of IPD
cases in those over 5 years of age did not change
significantly between 2005–2006 (5514 cases) and 2007–
2008 (5496 cases). Importantly, a recent increased
incidence of IPD caused by PCV7 NVTs has been detected
in all age groups, particularly involving serotypes 7F, 19A
and 22F (Kaye et al., 2009). These NVTs have also been
observed to cause an increased incidence of IPD in
countries outside the UK using PCV7, such 7F in
Portugal (Sa´-Lea˜o et al., 2009) and 19A and 22F in the
US (Hicks et al., 2007). The post-PCV7 19A increase in the
US was particularly associated with one multilocus
sequence type, ST320, a clone which had high antibiotic
resistance (Hanage et al., 2007; Pillai et al., 2009). This may
have been the driving force in its increase (Dagan et al.,
2009). However, the 19A clone increasing in the UK is
predominantly ST199 (Pichon et al., 2008), not ST320,
suggesting factors other than antibiotic resistance were
involved in causing this increase.
Vaccine inclusion of related serotypes within a serogroup
was previously assumed to confer some level of cross-
protection (Hausdorff et al., 2000). However, serotype 19A
IPD incidence has increased in the UK despite the fact that
the related serotype 19F was included in the vaccine. The
19F polysaccharide is known to be the least immunogenic
of the PCV7 VTs (Pletz et al., 2008), and in addition cross-
reaction of antibodies for 19F to 19A has also been shown
to be weak in vitro (Lee et al., 2009). In carriage, a
significant increase in the prevalence of serotype 6C has
been observed since PCV7 introduction in the UK (Nahm
et al., 2009; Tocheva et al., 2010). This is despite the
presence of the 6B polysaccharide in PCV7, which does
provide protection against 6A (Va¨keva¨inen et al., 2001). 6B
cross-reactivity does not extend to 6C, therefore the PCV7
elicits negligible or no immune protection against this
serotype (Park et al., 2007a). Serotypes related to the VTs
have contributed to serotype replacement more than was
perhaps first expected, potentially because they are in a
prime position to fill the specific niche vacated by their
counterpart in an environment under vaccine pressure.
Replacement disease has dramatically reduced the effec-
tiveness of PCV7 vaccination and is likely to be a major
factor in the decision to replace PCV7 with PCV13 in April
2010.
The most common serotypes causing IPD can change
rapidly. In Scotland, IPD-causing serotypes changed
considerably from 2005/2006 to 2009 (Table 2). In 2009,
7F was reported to be the most common IPD-causing
serotype in the under 5s, accounting for 12% of cases
(Kaye et al., 2009). Before the introduction of PCV7, this
serotype caused little disease; in fact, 7F was not isolated
from a single reported IPD case for children under 5 years
old in Scotland during 2006 (unpublished data). Dramatic
changes in serotype prevalence can occur over time. This
demonstrates the importance of long-term epidemiological
surveillance in allowing appropriate response and action to
changes.
It must also be noted that serotype distribution can
fluctuate substantially in the absence of vaccination. A
highly significant increase in serotype 1 was observed
within the UK prior to routine PCV7 immunization,
highlighting that other factors are also involved in
pneumococcal serotype dynamics (Jefferies et al., 2010;
Kirkham et al., 2006).
Although not the only cause, PCV7 is likely to have been
playing an important part in serotype fluctuations in the
UK by reducing VTs and creating a niche, which is being
filled by NVTs or other species of bacteria. Ongoing
surveillance and research will help uncover the reasons why
certain organisms appear better at filling this niche than
others, and why some cause invasive disease while others
cause little or none at all.
PCV7 coverage
Historically, PCV7 covered 90% of the serotypes causing
IPD in the US. Crucially, even before PCV7 introduction,
the disease serotype coverage in the UK was much lower. In
Scotland, only 76.5% of all IPD cases in those aged under 5
years old were calculated to be covered by PCV7 (Clarke
et al., 2006), whilst in the developing world coverage was
suggested to drop as low as 45% for IPD (Hausdorff et al.,
2000).
Pneumococci are the primary causal agent for pneumonia.
The impact of PCV7 on pneumonia is hard to quantify as
confirmed pneumococcal pneumonia cases are difficult to
define. Some result in IPD, while the majority probably do
not. Despite this variation, studies have indicated that
PCV7 efficacy for clinical and X-ray-defined pneumonia is
between 5% and 25% (Black et al., 2002; Lucero et al.,
2009). In addition, the incidence of pneumonia-related
hospitalization has decreased by up to 39% since PCV7
introduction in the US in children under 2 years old
(Grijalva et al., 2007; CDC, 2009). All-cause pneumonia
Table 2. Serotypes (no. of cases) involved in IPD in Scotland:
rank order of incidence in those ¡5 years old
Rank 2006* 2009D
1 14 (26) 7F (50)
2 1 (8) 1 (35)
3 19F (5) 8 (32)
4 6A (5) 3 (30)
5 6B (5) 19A (24)
6 9V (5) 22F (24)
*Our unpublished data.
DData from Shakir et al. (2009).
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cases remained stable during US PCV7 introduction,
suggestive of other species contributing to disease replace-
ment (CDC, 2009). Direct UK data regarding the impact of
PCV7 on lower respiratory tract infection are not available,
although it is likely that serotype replacement is occurring
for pneumococcal pneumonia, as has been reported for
IPD.
S. pneumoniae is also a leading cause of AOM. This non-
invasive disease is a particular issue in young children and
has a high economic burden worldwide (Melegaro et al.,
2006). Pneumococcal conjugate vaccines have been shown
to offer some protection against AOM (Eskola et al., 2001;
Prymula et al., 2006); additionally the incidence has been
shown to decrease in the US post-PCV7 (Black et al., 2004;
Block et al., 2004; Eskola et al., 2001; Prymula et al., 2006).
US cases of otitis media due to NVTs were also seen to
increase in incidence in the post-PCV7 era, a 10% rise in
NVTs was reported by one study (Block et al., 2004), along
with observations of capsular switch events (McEllistrem
et al., 2003). Serotype data for AOM in the UK and Europe
are scarce (Rodgers et al., 2009), although data from the US
suggest that serotype replacement, capsular switch and
species replacement may limit the effectiveness of pneu-
mococcal vaccination against otitis media in the UK.
Haemophilus influenzae is also an important cause of AOM,
specifically, non-typable H. influenzae (NTHi) AOM,
which was seen to increase by 15% following widespread
PCV7 vaccination in the US (Casey et al., 2010). Increases
in NTHi may also be filling part of the niche left by
pneumococcal VTs in the UK.
Over time, PCV immunization will continue to impact on
serotype prevalence and affect the incidence of pneumo-
coccal disease. This impact will reduce current vaccine
efficacy, confirming the need for ongoing vaccine devel-
opment to ensure control of pneumococcal disease.
Vaccine progression
PHiD-CV and PCV13 are now both licensed in the UK,
with Prevenar 13 having replaced Prevenar in the UK
immunization programme. These vaccines target addi-
tional serotypes that are important to current disease
incidence and are not well targeted by PCV7 (Table 3).
The PHiD-CV developed by GlaxoSmithKline includes two
capsular polysaccharide types conjugated to either diph-
theria (serotype 19F) or tetanus (serotype 18C) toxoid, and
eight others (1, 4, 5, 6B, 7F, 9V, 14, 23F) conjugated to
NTHi protein D (Wysocki et al., 2009). This is said to give
PHiD-CV the extra ability of providing some protection
against AOM caused by NTHi and therefore may influence
the impact and cost-effectiveness of this vaccine (Wysocki
et al., 2009). Originally, the GlaxoSmithKline experimental
vaccine included 11 serotypes, yet the inclusion of serotype
3 was rejected due to a lack of inducible immunogenicity
during clinical trials (Prymula et al., 2006). The PCV13
developed by Wyeth (now Pfizer) targets the same
pneumococcal serotypes as the PHiD-CV plus three
additional serotypes, all conjugated to the immunogenic
diphtheria toxoid (Scott et al., 2007). Notably, 22F is not
targeted by the PHiD-CV or PCV13, and this serotype has
dramatically increased in IPD prevalence in children under
2 years of age in England and Wales (Kaye et al., 2009). 22F
is also now ranked sixth in Scotland for IPD in children
under 5 (Table 2).
PHiD-CV and PCV13 coverage
Based on national (England and Wales) surveillance data,
the percentage of serotypes causing cases of IPD covered by
PCV7, PHiD-CV and PCV13 was calculated (Kaye et al.,
2009). In 2007–2008, only 24% of IPD cases in those under
5 years old were caused by serotypes covered by PCV7, in
stark contrast to the 76.5% UK estimate based on IPD
coverage in this age group prior to vaccine implementation
(Clarke et al., 2006). The serotype coverage of IPD in
children under 5 years of age for PHiD-CV and PCV13 was
53% and 74%, respectively, for 2007/2008, a dramatic
decrease from the 81% and 92% 2005/2006 coverage. A
fundamental observation is that the potential coverage of
PHiD-CV and PCV13 had already decreased prior to
implementation due to the routine use of PCV7 and the
associated serotype replacement, as well as shifts in
pneumococcal epidemiology caused by other non-vaccine
factors.
Clinical trials and mathematical models offer a basis for
prediction of vaccine impact. One study used an algorithm
that suggested that the PHiD-CV will be at least as effective
as PCV7 in protecting against pneumococcal invasive
disease worldwide (Hausdorff et al., 2009), although the
design of such an algorithm is complex and based on
assumptions which may affect the model output. In clinical
trials, the study population will naturally be exposed to
multifaceted epidemiological factors that will affect vaccine
Table 3. Serotypes included in the 7-, 10- and 13-valent PCVs
Data from Black et al. (2000), Scott et al. (2007) and Wysocki et al. (2009). Bold and underlined text indicates serotypes not included in PCV7.
Vaccine Manufacturer Serotypes UK status
PCV7 (Prevenar) Pfizer 4, 6B, 9V, 14, 18C, 19F, 23F Licensed
PHiD-CV (Synflorix) GlaxoSmithKline 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F Licensed
PCV13 (Prevenar 13) Pfizer 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Licensed in use
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impact in the target population. A German clinical study,
powered to show immunological non-inferiority, showed
that PCV13 should be just as effective as PCV7 at
protecting against the seven serotypes included within the
PCV7, as well as inducing sufficient immunity for the
further VTs (Kieninger et al., 2008). Importantly, PCV13
was shown to induce an opsonophagocytic activity to
serotype 19A, which indicates that it will be efficient in
preventing cases of serotype 19A invasive disease
(Kieninger et al., 2008).
Both PHiD-CV and PCV13 are likely to be effective in
reducing IPD and non-invasive disease. However, the
relative effect of PHiD-CV compared to PCV13 immun-
ization on the prevention of combined pneumococcal and
NTHi invasive or all-cause disease has not yet been
established. As well as the effect on invasive diseases,
pneumococcal carriage in individuals and the population is
affected by routine immunization of the population, and
the serotype effects appear to differ from those seen in
invasive disease (unpublished data).
Invasive potential
Pneumococcal serotypes are known to differ in their
invasiveness (Smith et al., 1993). Traditionally the
serotypes chosen for vaccine inclusion have been based
on the rank order incidence of disease. These serotypes are
often the most prevalent in carriage but they are not
necessarily those with the highest potential for invasive-
ness (Brueggemann et al., 2003, 2004). By targeting the
serotypes in rank order of disease incidence, any serotype
replacement that occurs may result in increased prevalence
of a particularly invasive serotype. Several studies have
calculated the potential of an individual serotype causing
a disease case, taking into account factors such as the
prevalence in carriage (Ba¨ttig et al., 2006; Brueggemann
et al., 2004; Hanage et al., 2005). One study highlighted
that moderately prevalent NVT serotypes 3, 8, 33 and 38 all
had similar potential to cause invasive disease as the VT
6B, 19F and 23F, previously responsible for a consider-
able proportion of disease cases in the pre-vaccine era
(Brueggemann et al., 2004). If a shift in prevalence
occurred, for example, reduced VT 23F with increased
NVT 8, this could then potentially result in serotype 8
having a similar disease incidence as VT 23F previously.
NVT 19A and 7F, which have recently increased as a cause
of IPD in the UK (Kaye et al., 2009), have also previously
been reported to be associated with invasive disease
(Brueggemann et al., 2003; Sjo¨stro¨m et al., 2006). This
may indicate that greater virulence of a serotype has been
central to the rise in case numbers rather than an
expansion of clones with these serotypes.
The presence of serotypes in PHiD-CV and PCV13
additional to those contained within PCV7 will, to some
degree, help to protect against the emergence of some
previously under-represented serotypes with significant
invasive potential.
Future work
Data are only just becoming available on post-PCV7
pneumococcal carriage in the UK due to the time vaccine
implementation has taken to translate into altered carriage
and for the collection of comparable data. Further serotype
data are also required for pneumonia and AOM, although
these are not collected routinely by UK surveillance
systems. A more detailed understanding of the dynamics
of serotype prevalence is central to sustaining the control of
pneumococcal disease.
Due to the global variation in serotype prevalence, vaccine
design and use would preferably be specific to a geographi-
cal area, although this is unrealistic due to the time and cost
involved in vaccine development. Future vaccines may have
broader global application if design can employ more
complex epidemiological models to simulate serotype
replacement. One alternative is the use of vaccines based
on highly conserved, immunogenic pneumococcal surface
proteins that are involved in bacterial virulence. Current
candidate proteins include pneumococcal surface protein A
(PspA), pneumococcal surface protein C (PspC), pneumo-
lysin (Ply) and caseinolytic protease (ClpP) (Cao et al., 2007;
Hamel et al., 2004). Proteins could potentially be used in
combination to maximize synergistic effects potentially
providing protection from most, if not all, isolates of
pneumococci (Cao et al., 2007; Morsczeck et al., 2008).
Protein-based vaccines could potentially give broad protec-
tion from pneumococcal infection independent of serotype
and invasiveness. However, such vaccines would also be
predicted to have major effects on overall pneumococcal
carriage with as yet unknown clinical significance of non-
pneumococcal bacterial replacement. Establishing protection
against otitis media and carriage would also ideally require
stimulation of a mucosal antibody response (Zhang et al.,
2002). If proven to be safe in both direct and indirect effects,
additional advantages of protein-only vaccines could be the
induction of T-cell responses and ease of vaccine formulation
resulting in reduced production costs when compared to
conjugate vaccines. At present, candidate proteins are being
evaluated in murine models, including the demonstration of
passive immunity from polyclonal antibodies against specific
pneumococcal proteins (Cao et al., 2007, 2009; Morsczeck
et al., 2008; Ogunniyi et al., 2007).
Summary
Four winters after PCV7 introduction to the UK routine
infant immunization programme, the positive impact is
clear. There has been a significant reduction in the
incidence of PCV7 serotypes causing pneumococcal IPD
in those under 5 years old, together with the induction of
herd immunity. However, serotype replacement has
occurred, such that IPD incidence in those under 2 years
of age is now similar to that prior to PCV7 introduction.
Serotype replacement has been observed for invasive and
non-invasive pneumococcal disease worldwide, and it is
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evident that the overall effectiveness of PCV7 on the total
pneumococcal disease burden has reduced. In April 2010,
PCV13 replaced PCV7 in the UK infant immunization
programme, and it is important to note that no older child
catch-up campaign has been implemented (Department of
Health, 2010). The presence of additional serotypes within
PCV13 will help to combat the serotype replacement
observed. Many additional factors will influence the
serotype shifts in carriage and disease, including capsular
switch events and presence of antimicrobial resistance.
Nevertheless, pneumococcal vaccines based on a limited
number of serotypes will continue to have a limited
lifespan due to the selection pressure vaccines exert and the
diversity of the bacteria. Increased vaccine coverage and
control of pneumococcal disease is required worldwide,
not only in the UK and other Western countries.
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